<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05041179</url>
  </required_header>
  <id_info>
    <org_study_id>18.01.CLI</org_study_id>
    <nct_id>NCT05041179</nct_id>
  </id_info>
  <brief_title>Bioavailability of PRUVIN® and Its Effects in Healthy Subjects (INDIGO)</brief_title>
  <official_title>Investigation on the Bioavailability of PRUVIN® and Its Effects on Physiologic-metabolic Biomarkers in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nestlé</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nestlé</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the effect of different doses of PRUVIN® (N-acetylcysteine [NAC] and glycine) on&#xD;
      reduced glutathione levels in healthy elderly subjects&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single-center, double-blind, randomized, placebo-controlled 4-arm study-design, to&#xD;
      assess the safety, tolerability and effect of PRUVIN® on reduced glutathione levels in&#xD;
      healthy elderly (age 60-85 years) subjects.&#xD;
&#xD;
      In addition, baseline values of glutathione precursors, glutathione, and plasma markers of&#xD;
      oxidative stress in a healthy young cohort (non-interventional) will be compared with those&#xD;
      of the healthy elderly cohort (interventional).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 1, 2019</start_date>
  <completion_date type="Actual">May 1, 2020</completion_date>
  <primary_completion_date type="Actual">April 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Double-blind, randomized, Placebo-controlled</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total reduced glutathione</measure>
    <time_frame>2 weeks</time_frame>
    <description>Total reduced glutathione (GSH-T) in whole-blood normalized to hematocrit</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Free reduced glutathione</measure>
    <time_frame>2 weeks</time_frame>
    <description>Free reduced glutathione (GSH-F), free reduced glutathione to oxidized glutathione disulfide ratio (GSH-F:GSSG)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hematocrit</measure>
    <time_frame>2 weeks</time_frame>
    <description>Whole-blood concentrations of glycine and cysteine normalized to hematocrit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lipid oxidation</measure>
    <time_frame>2 weeks</time_frame>
    <description>Lipid oxidation derived from indirect calorimetry</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">128</enrollment>
  <condition>Oxidative Stress</condition>
  <arm_group>
    <arm_group_label>7.2 g of actives (3.6 g NAC and 3.6 g glycine) per day split in two doses (arm A)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>First dose (1.8 g NAC and 1.8 g glycine) consumed in the morning&#xD;
Second dose (1.8 g NAC and 1.8 g glycine) taken in the evening</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4.8 g of actives (2.4 g NAC and 2.4 g glycine) per day split in two doses (arm B)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>First dose (1.2 g NAC and 1.2 g glycine, +1.2 g placebo) consumed in the morning&#xD;
Second dose (1.2 g NAC and 1.2 g glycine, +1.2 g placebo) taken in the evening</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2.4 g of actives (1.2 g NAC and 1.2 g glycine) per day split in two doses (arm C)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>First dose (0.6 g NAC and 0.6 g glycine, +2.4 g placebo) consumed in the morning&#xD;
Second dose (0.6 g NAC and 0.6 g glycine, +2.4 g placebo) taken in the evening</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo control (7.2 g isomaltulose)(arm D)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>First dose (3.6 g isomaltulose) consumed in the morning&#xD;
Second dose (3.6 g isomaltulose) taken in the evening</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Pruvin R</intervention_name>
    <description>Combination of N-acetylcysteine an glycine</description>
    <arm_group_label>2.4 g of actives (1.2 g NAC and 1.2 g glycine) per day split in two doses (arm C)</arm_group_label>
    <arm_group_label>4.8 g of actives (2.4 g NAC and 2.4 g glycine) per day split in two doses (arm B)</arm_group_label>
    <arm_group_label>7.2 g of actives (3.6 g NAC and 3.6 g glycine) per day split in two doses (arm A)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Isomaltulose</intervention_name>
    <description>Placebo as comparator to intervention</description>
    <arm_group_label>Placebo control (7.2 g isomaltulose)(arm D)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Non-interventional cohort:&#xD;
&#xD;
        Inclusion criteria:&#xD;
&#xD;
          1. 20-40 years, both inclusive&#xD;
&#xD;
          2. male and female&#xD;
&#xD;
          3. Considered generally healthy upon completion of medical history and screening safety&#xD;
             assessments, as judged by the Investigator.&#xD;
&#xD;
          4. BMI &gt;18.5 and &lt;30.0 kg/m2&#xD;
&#xD;
          5. HbA1c &lt;5.7 %&#xD;
&#xD;
          6. Informed consent as documented by signature&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          1. Receipt of any medicinal product or nutritional product in clinical development within&#xD;
             30 days before enrollment in this trial.&#xD;
&#xD;
          2. Any history or presence of clinically relevant comorbidity, as judged by the&#xD;
             Investigator.&#xD;
&#xD;
          3. Signs of acute illness as judged by the Investigator.&#xD;
&#xD;
          4. Any serious systemic infectious disease during four weeks prior enrollment in this&#xD;
             trial&#xD;
&#xD;
          5. Clinically significant abnormal screening laboratory tests, as judged by the&#xD;
             Investigator.&#xD;
&#xD;
          6. AST and/or ALT &gt; 2 times the upper limit of normal.&#xD;
&#xD;
          7. Elevated serum creatinine values above the upper limit of normal.&#xD;
&#xD;
          8. Systolic blood pressure &lt; 90 mmHg or &gt;139 mmHg and/or diastolic blood pressure &lt; 50&#xD;
             mmHg or &gt;89 mmHg (excluding white-coat hypertension; therefore, a repeat test showing&#xD;
             results within range will be acceptable).&#xD;
&#xD;
          9. Heart rate at rest outside the range of 50-90 beats per minute.&#xD;
&#xD;
         10. Clinically significant abnormal standard 12-lead electrocardiogram (ECG) after 5&#xD;
             minutes resting in supine position at screening, as judged by the Investigator.&#xD;
&#xD;
         11. Significant history of alcoholism or drug abuse as judged by the Investigator&#xD;
             consuming more than 24 grams alcohol/day (for males), 12 grams alcohol/day (for&#xD;
             females) on average.&#xD;
&#xD;
         12. Smoking or use of nicotine substitute products.&#xD;
&#xD;
         13. Any medication (prescription and non-prescription drugs) within 14 days before&#xD;
             screening.&#xD;
&#xD;
         14. Blood donation or blood loss of more than 500 mL within the last 3 months prior to&#xD;
             screening.&#xD;
&#xD;
         15. Mental incapacity, unwillingness or language barriers precluding adequate&#xD;
             understanding or co-operation.&#xD;
&#xD;
         16. If female, pregnant or breast-feeding.&#xD;
&#xD;
         17. Consumption of high protein supplements within 60 days of screening and during the&#xD;
             study.&#xD;
&#xD;
         18. Consumption of any antioxidant, vitamins, and herbals (see chapter 12.2) supplements&#xD;
             within 2 weeks prior to screening and during the study.&#xD;
&#xD;
        Interventional Cohort:&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          1. 60-85 years, both inclusive&#xD;
&#xD;
          2. male and female&#xD;
&#xD;
          3. Sedentary, less than 1h of strenuous physical exercise per week&#xD;
&#xD;
          4. BMI of 25.0 to 35.0 kg/m2, both inclusive&#xD;
&#xD;
          5. HbA1c&lt;6.5 %&#xD;
&#xD;
          6. Informed consent as documented by signature&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Known or suspected hypersensitivity to any component of the trial products.&#xD;
&#xD;
          2. Receipt of any medicinal product or nutritional product in clinical development within&#xD;
             30 days before randomisation in this trial.&#xD;
&#xD;
          3. History of multiple and/or severe allergies to drugs or foods or a history of severe&#xD;
             anaphylactic reaction.&#xD;
&#xD;
          4. Any history or presence of clinically relevant comorbidity, as judged by the&#xD;
             Investigator.&#xD;
&#xD;
          5. Signs of acute illness as judged by the Investigator.&#xD;
&#xD;
          6. Any serious systemic infectious disease during four weeks prior to first intake of the&#xD;
             trial product, as judged by the Investigator.&#xD;
&#xD;
          7. Clinically significant abnormal screening laboratory tests, as judged by the&#xD;
             Investigator.&#xD;
&#xD;
          8. AST and/or ALT &gt; 2 times the upper limit of normal.&#xD;
&#xD;
          9. Elevated serum creatinine values above the upper limit of normal.&#xD;
&#xD;
         10. Systolic blood pressure &lt; 90 mmHg or &gt;139 mmHg and/or diastolic blood pressure &lt; 50&#xD;
             mmHg or &gt;89 mmHg (excluding white-coat hypertension; therefore, a repeat test showing&#xD;
             results within range will be acceptable).&#xD;
&#xD;
         11. Heart rate at rest outside the range of 50-90 beats per minute.&#xD;
&#xD;
         12. Clinically significant abnormal standard 12-lead electrocardiogram (ECG) after 5&#xD;
             minutes resting in supine position at screening, as judged by the Investigator.&#xD;
&#xD;
         13. Significant history of alcoholism or drug abuse as judged by the Investigator&#xD;
             consuming more than 24 grams alcohol/day (for males), 12 grams alcohol/day (for&#xD;
             females) on average.&#xD;
&#xD;
         14. Smoking more than 5 cigarettes or the equivalent per day.&#xD;
&#xD;
         15. Inability or unwillingness to refrain from smoking and use of nicotine substitute&#xD;
             products 3 days prior and during the intervention.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ulrike Hövelmann, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Profil Institut für Stoffwechselforschung GmbH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Profil Institut für Stoffwechselforschung GmbH</name>
      <address>
        <city>Neuss</city>
        <zip>41460</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>September 2, 2021</study_first_submitted>
  <study_first_submitted_qc>September 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 10, 2021</study_first_posted>
  <last_update_submitted>September 2, 2021</last_update_submitted>
  <last_update_submitted_qc>September 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Glutathione</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

